Evidence map›Paper›PMID 39365849›Full record

ArticleJMIR medical informatics2024

Practical Aspects of Using Large Language Models to Screen Abstracts for Cardiovascular Drug Development: Cross-Sectional Study.

Jay G Ronquillo, Jamie Ye, Donal Gorman, Adina R Lemeshow, Stephen J Watt

Abstract read
In one paragraph

Article in JMIR medical informatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Jay G RonquilloWorldwide Medical and Safety, Pfizer Research and Development, Pfizer Inc, New York, NY, United States.ORCID 0000-0002-0438-7172
Jamie YeWorldwide Medical and Safety, Pfizer Research and Development, Pfizer Inc, New York, NY, United States.ORCID 0000-0003-3024-4711
Donal GormanPfizer Research and Development UK Ltd, Cambridge, United Kingdom.ORCID 0000-0003-4853-9817
Adina R LemeshowWorldwide Medical and Safety, Pfizer Research and Development, Pfizer Inc, New York, NY, United States.ORCID 0000-0003-2994-1341
Stephen J WattWorldwide Medical and Safety, Pfizer Research and Development, Pfizer Inc, New York, NY, United States.ORCID 0000-0003-1403-5493

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Unlabelled: Cardiovascular drug development requires synthesizing relevant literature about indications, mechanisms, biomarkers, and outcomes. This short study investigates the performance, cost, and prompt engineering trade-offs of 3 large language models accelerating the literature screening process for cardiovascular drug development applications.

Indexed as

Drug DevelopmentAbstracting and IndexingCardiovascular AgentsCardiovascular DiseasesCross-Sectional StudiesHumansNatural Language ProcessingCardiovascular AgentsAIartificial intelligencebiomarkerbiomedicalbiomedical informaticscardiocardiologycardiovascularcross-sectional studydrugdrug developmentGPTlarge language modelLLMscreening optimization

Identifiers

PMID39365849
PMCPMC11469161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.